ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conference
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN ) , a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) antibody-drug conjugate (ADC) technology, today announced that Gregory Perry, Executive Vice President and Chief Financial Officer, will present at the upcoming Credit Suisse Antibody Day in New York. The presentation is scheduled for 2:00 pm ET on May 10, 2013.
This webcast will be accessible live through the “Investor Information” section of the Company’s website, www.immunogen.com; a replay will be available at the same location for approximately a week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's TAP technology uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. Ten TAP compounds are now in the clinic, of which three are wholly owned by the Company. The most advanced compound using ImmunoGen's TAP technology, Kadcyla™, has been approved for marketing in the US and is undergoing regulatory review in Europe and Japan; it is being commercialized in the US by Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.
Kadcyla™ is a trademark of Genentech.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
KEYWORDS: United States North America Massachusetts New York